Back to top
more

HealthEquity (HQY)

(Delayed Data from NSDQ)

$80.98 USD

80.98
532,086

+1.22 (1.53%)

Updated Jul 26, 2024 04:00 PM ET

After-Market: $80.98 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Medical Services

Better trading starts here.

Zacks News

What's in Store for GW Pharmaceuticals' (GWPH) Q4 Earnings?

GW Pharmaceuticals (GWPH) Q4 results likely to reflect top-line growth on strong adoption of Epidiolex and Sativex.

HealthEquity (HQY) Stock Up on Solid Fiscal 2020 Results

HealthEquity (HQY) raises fiscal 2020 view for top and bottom line.

Trina Mukherjee headshot

3 Medical Product Stocks Likely to Beat This Earnings Season

Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.

Sonoco (SON) Meets Q4 Earnings Estimates

Sonoco (SON) delivered earnings and revenue surprises of 0.00% and 0.35%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

HealthEquity (HQY) to Report Q4 Earnings: What's in Store?

HealthEquity's (HQY) fourth-quarter fiscal 2020 earnings are likely to reflect top-line growth and higher HSA member growth.

Global Industrial Unit to Drive Ecolab's (ECL) Q4 Earnings

Ecolab's (ECL) Q4 results are likely to reflect strength in core Global Industrial unit.

AMN vs. HQY: Which Stock Should Value Investors Buy Now?

AMN vs. HQY: Which Stock Is the Better Value Option?

Here's Why You Should Hold on to OPKO Health Stock for Now

OPKO Health (OPK) continues to gain from RAYALDEE and BioReference platforms, and focus on R&D despite operating losses.

ABIOMED (ABMD) to Report Q3 Earnings: What's in the Offing?

Flagship Impella likely to have boosted ABIOMED's (ABMD) fiscal Q3 earnings.

Sanghamitra Saha headshot

Bet on Earnings Beat With 5 Top-Ranked Stocks

These top-ranked stocks are likely to beat on bottom line in their next releases.

Varian (VAR) Earnings and Revenues Miss Estimates in Q1

Varian (VAR) gains from core Oncology segment in fiscal Q1.

Quest Diagnostics (DGX) Hits a 52-Week High: What's Driving the Stock?

Quest Diagnostics (DGX) gains from several positive developments like partnerships and acquisitions.

Accuray (ARAY) Q2 Earnings Top Estimates, Gross Orders Fall

Service revenues drive Accuray's (ARAY) Q2 results, gross margin expands.

Here's Why You Should Add HealthEquity (HQY) to Portfolio Now

Solid prospects in the HSA industry consistently drive HealthEquity (HQY).

Here's Why You Should Invest in Intuitive Surgical Stock Now

Intuitive Surgical (ISRG) continues to benefit from da Vinci surgical system, strong global foothold and solid recurring revenue base.

HealthEquity (HQY) Dips More Than Broader Markets: What You Should Know

HealthEquity (HQY) closed the most recent trading day at $70.58, moving -1.64% from the previous trading session.

Intuitive Surgical (ISRG) Q4 Earnings Top, Margins Expand

Intuitive Surgical (ISRG) gains from solid international show in Q4.

NextGen (NXGN) Earnings and Revenues Beat Estimates in Q3

NextGen (NXGN) gains from Recurring revenues in Q3, bookings down.

Sapna Bagaria headshot

Teladoc (TDOC) Hits 52-Week High: Will Momentum Sustain?

Teladoc (TDOC) stock gains from from positive earnings pre-announcement and news to acquire InTouch Health.

Here's Why You Should Add DexCom (DXCM) to Your Portfolio

DexCom (DXCM) expects its strong product portfolio to consistently drive top line.

Nevro (NVRO) Gains Ground on Solid Preliminary Q4 Results

Higher revenues and upbeat 2020 worldwide revenue outlook benefit Nevro's (NVRO) preliminary Q4 results.

Allscripts Expands Partnership With PIH Health Through 2025

Encouraged by its solid EHR prospects, Allscripts (MDRX) expects a surge in its fourth-quarter 2019 bookings.

Inogen (INGN) Announces Preliminary Q4 Results, Slashes View

Inogen (INGN) expects direct-to-consumer sales to be its fastest-growing channel in 2020.

ABIOMED (ABMD) Announces Preliminary Q3 Results, Slashes View

ABIOMED's (ABMD) Q3 international revenues grew year over year; fiscal 2020 view slashed.

Teladoc to Buy InTouch Health, Expand Reach in Virtual Care

Teladoc (TDOC) to acquire InTouch Health and provide virtual health solutions ranging from critical to everyday care.